> top > docs > PubMed:33338232 > annotations

PubMed:33338232 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
3 0-10 Chemical denotes Sofosbuvir MESH:D000069474
4 15-26 Chemical denotes daclatasvir MESH:C549273
5 48-56 Disease denotes COVID-19 MESH:C000657245
33 184-209 Disease denotes novel coronavirus disease MESH:C000657245
34 216-224 Disease denotes COVID-19 MESH:C000657245
35 255-265 Chemical denotes sofosbuvir MESH:D000069474
36 270-281 Chemical denotes daclatasvir MESH:C549273
37 329-337 Disease denotes COVID-19 MESH:C000657245
38 338-347 Disease denotes infection MESH:D007239
39 431-439 Disease denotes COVID-19 MESH:C000657245
40 441-449 Species denotes Patients Tax:9606
41 497-519 Chemical denotes sofosbuvir/daclatasvir
42 525-543 Chemical denotes hydroxychloroquine MESH:D006886
43 571-589 Chemical denotes hydroxychloroquine MESH:D006886
44 742-749 Disease denotes Fatigue MESH:D005221
45 751-759 Disease denotes dyspnoea MESH:D004417
46 764-780 Disease denotes loss of appetite MESH:D001068
47 967-975 Species denotes patients Tax:9606
48 1019-1041 Chemical denotes sofosbuvir/daclatasvir
49 1217-1224 Species denotes patient Tax:9606
50 1257-1279 Chemical denotes sofosbuvir/daclatasvir
51 1385-1393 Species denotes patients Tax:9606
52 1403-1410 Disease denotes fatigue MESH:D005221
53 1418-1440 Chemical denotes sofosbuvir/daclatasvir
54 1511-1533 Chemical denotes sofosbuvir/daclatasvir
55 1677-1699 Chemical denotes sofosbuvir/daclatasvir
56 1745-1767 Chemical denotes Sofosbuvir/daclatasvir
57 1804-1812 Species denotes patients Tax:9606
58 1818-1825 Disease denotes fatigue MESH:D005221
59 1830-1838 Disease denotes dyspnoea MESH:D004417

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 742-749 Phenotype denotes Fatigue http://purl.obolibrary.org/obo/HP_0012378
T2 751-759 Phenotype denotes dyspnoea http://purl.obolibrary.org/obo/HP_0002094
T3 1403-1410 Phenotype denotes fatigue http://purl.obolibrary.org/obo/HP_0012378
T4 1818-1825 Phenotype denotes fatigue http://purl.obolibrary.org/obo/HP_0012378
T5 1830-1838 Phenotype denotes dyspnoea http://purl.obolibrary.org/obo/HP_0002094

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-114 Sentence denotes Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.
T2 115-128 Sentence denotes INTRODUCTION:
T3 129-226 Sentence denotes Effective treatments are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19).
T4 227-348 Sentence denotes This trial aims to evaluate sofosbuvir and daclatasvir versus standard care for outpatients with mild COVID-19 infection.
T5 349-357 Sentence denotes METHODS:
T6 358-440 Sentence denotes This was a randomized controlled clinical trial in outpatients with mild COVID-19.
T7 441-596 Sentence denotes Patients were randomized into a treatment arm receiving sofosbuvir/daclatasvir plus hydroxychloroquine or a control arm receiving hydroxychloroquine alone.
T8 597-681 Sentence denotes The primary endpoint of the trial was symptom alleviation after 7 days of follow-up.
T9 682-741 Sentence denotes The secondary endpoint of the trial was hospital admission.
T10 742-826 Sentence denotes Fatigue, dyspnoea and loss of appetite were investigated after 1 month of follow-up.
T11 827-916 Sentence denotes This study is registered with the IRCT.ir under registration number IRCT20200403046926N1.
T12 917-925 Sentence denotes RESULTS:
T13 926-1093 Sentence denotes Between 8 April 2020 and 19 May 2020, 55 patients were recruited and allocated to either the sofosbuvir/daclatasvir treatment arm (n = 27) or the control arm (n = 28).
T14 1094-1154 Sentence denotes Baseline characteristics were similar across treatment arms.
T15 1155-1212 Sentence denotes There was no significant difference in symptoms at Day 7.
T16 1213-1352 Sentence denotes One patient was admitted to hospital in the sofosbuvir/daclatasvir arm and four in the control arm, but the difference was not significant.
T17 1353-1482 Sentence denotes After 1 month of follow-up, two patients reported fatigue in the sofosbuvir/daclatasvir arm and 16 in the control arm; P < 0.001.
T18 1483-1495 Sentence denotes CONCLUSIONS:
T19 1496-1623 Sentence denotes In this study, sofosbuvir/daclatasvir did not significantly alleviate symptoms after 7 days of treatment compared with control.
T20 1624-1744 Sentence denotes Although fewer hospitalizations were observed in the sofosbuvir/daclatasvir arm, this was not statistically significant.
T21 1745-1853 Sentence denotes Sofosbuvir/daclatasvir significantly reduced the number of patients with fatigue and dyspnoea after 1 month.
T22 1854-1897 Sentence denotes Larger, well-designed trials are warranted.